VSTM Verastem Inc.

1.54
0  0%
Previous Close 1.54
Open 1.59
Price To Book 1.64
Market Cap 113770486
Shares 73,876,939
Volume 1,219,102
Short Ratio
Av. Daily Volume 3,028,739

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 presentation ASCO June 2018.
Duvelisib
Peripheral T-Cell Lymphoma (PTCL)
Phase 1/2 initiation of dosing announced January 26, 2017.
Avelumab and defactinib
Ovarian cancer
Phase 1/2 initial data - 21st Congress of European Hematology Association June 9 - 12, 2016
Duvelisib - Conetempo
Treatment-naïve patients with follicular lymphoma
Phase 2 data released June 2016 - short of expectations
Duvelisib (IPI-145) DYNAMO
Indolent non-Hodgkin lymphoma
FDA Approval announced September 24, 2018.
Duvelisib - DUO
Chronic lymphocytic leukemia (CLL)//Small Lymphocytic Lymphoma (SLL)/Follicular Lymphoma
Phase 2 interim analysis showed lack of efficacy. Trial stopped. September 2015
VS-6063
Mesothelioma prior to surgery
Phase 2 failed to meet endpoint - Jan 2015
Duvelisib (IPI-145)
Rheumatoid arthritis

Latest News

  1. Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
  2. Edited Transcript of VSTM earnings conference call or presentation 9-May-19 8:30pm GMT
  3. Verastem Oncology to Present New COPIKTRA™ (Duvelisib) Dose Modification Data from Patients Treated in the Phase 3 DUO Study
  4. Verastem Inc (VSTM) Q1 2019 Earnings Call Transcript
  5. Verastem (VSTM) Reports Q1 Loss, Lags Revenue Estimates
  6. Verastem: 1Q Earnings Snapshot
  7. Verastem Oncology Reports First Quarter 2019 Financial Results
  8. Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019
  9. Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility
  10. Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  11. Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
  12. Edited Transcript of VSTM earnings conference call or presentation 12-Mar-19 8:30pm GMT
  13. 3 Penny Stocks That Could Make You Rich -- or Regretful
  14. Why Verastem Stock Broke Down Today
  15. Verastem (VSTM) Q4 2018 Earnings Conference Call Transcript
  16. The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie
  17. Verastem (VSTM) Reports Q4 Loss, Misses Revenue Estimates
  18. Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments
  19. Verastem Oncology to Present at Upcoming Investor Conferences